SARS-CoV-2 anti-spike antibodies after a fourth dose of COVID-19 vaccine in adult solid-organ transplant recipients.

Autor: Perrier Q; Pharmacy Department, Grenoble Alpes University Hospital and Univ. Grenoble Alpes, Laboratory of Fundamental and Applied Bioenergetic (LBFA), INSERM U1055, Grenoble, France., Lupo J; Virology Laboratory, Grenoble Alpes University Hospital and Univ. Grenoble Alpes, Institut de Biologie Structurale (IBS), CEA, CNRS, Grenoble, France., Gerster T; Hepatogastroenterology Department, Grenoble Alpes University Hospital, Grenoble, France., Augier C; Cardiology Department, Grenoble Alpes University Hospital, Grenoble, France., Falque L; Pneumology and Physiology Department, Grenoble Alpes University Hospital, Grenoble, France., Rostaing L; Nephrology, Hemodialysis, Apheresis and Kidney Transplantation Department, Grenoble Alpes University Hospital and Univ. Grenoble Alpes, Grenoble, France., Pelletier L; Virology Laboratory, Grenoble Alpes University Hospital, Grenoble, France., Bedouch P; Pharmacy Department, Grenoble Alpes University Hospital and Univ. Grenoble Alpes, CNRS, TIMC-IMAG, Grenoble, France., Blanc M; Infectious Diseases Department, Grenoble Alpes University Hospital and Univ. Grenoble Alpes, Groupe de Recherche en Infectiologie Clinique, CIC-1406, INSERM, Grenoble, France., Saint-Raymond C; Pneumology and Physiology Department, Grenoble Alpes University Hospital, Grenoble, France., Boignard A; Cardiology Department, Grenoble Alpes University Hospital, Grenoble, France., Bonadona A; Hepatogastroenterology Department, Grenoble Alpes University Hospital, Grenoble, France., Noble J; Nephrology, Hemodialysis, Apheresis and Kidney Transplantation Department, Grenoble Alpes University Hospital and Univ. Grenoble Alpes, Grenoble, France., Epaulard O; Infectious Diseases Department, Grenoble Alpes University Hospital and Univ. Grenoble Alpes, Groupe de Recherche en Infectiologie Clinique, CIC-1406, INSERM, Grenoble, France. Electronic address: oepaulard@chu-grenoble.fr.
Jazyk: angličtina
Zdroj: Vaccine [Vaccine] 2022 Oct 19; Vol. 40 (44), pp. 6404-6411. Date of Electronic Publication: 2022 Sep 06.
DOI: 10.1016/j.vaccine.2022.08.065
Abstrakt: Background: A fourth dose of SARS-CoV-2 vaccine is recommended in solid-organ transplant (SOT) recipients, but the immunogenicity is poorly known.
Methods: We conducted a retrospective, observational, monocentric study between the 1st January 2021 and 31st March 2022 of the anti-Spike antibody titers after one to four doses of vaccine in SOT.
Results: 825 SOT were included. Median age at first vaccine injection was 61.2 (IQR 50.9-69.3) years; 66.7 % were male; 63.4 % had received four vaccine doses. The proportion of participants with a strong humoral response (>260 BAU/mL) increased with the number of vaccine doses: 10.6 % after the 1st dose (D1), 35.1 % after the 2nd (D2), 48.5 % after the 3rd (D3), and 65.1 % after the 4th (D4) (p < 0.001). Among the tested patients, the proportion with a detectable humoral response was significantly higher after D4 than after D3 (47 % vs 22 %, p = 0.01). Liver transplant recipients had more frequently a strong humoral response after D2, D3 and D4 (OR = 5.3, 3.7 and 6.6 respectively when compared with other organ transplant recipients, p < 0.001). In kidney transplant recipients, belatacept-containing regimen was associated with a lower rate of detectable humoral (9 % vs 40 %, p = 0.025) after D3, but there was no statistical difference after D4.
Conclusion: A fourth dose should be proposed to SOT recipients who did not developed an immune response after 3 doses. Kidney transplant recipients receiving belatacept have a poorer, although frequently detectable response.
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2022 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: